drugset

drugset / Trial / NCT00160589

LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)

NCT00160589 ↗

Phase 4 Completed 729 enrolled UCB Pharma

RandomizedParallel-groupDouble-blind

Summary

Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)

Timeline

Start: 2005-04
Primary completion: 2005-09
Completion: 2005-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Levocetirizine	Unknown	5 mg	Oral

Indications